Ordway Research Institute, Albany, NY 12208, USA.
J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii61-7. doi: 10.1093/jac/dkr100.
The factors associated with identifying an appropriate dose and schedule of an antimicrobial agent for treatment of hospitalized, seriously ill patients with pneumonia are straightforward. Information is required about the potency of the agent for typical pathogens likely to be encountered with pneumonia. It is helpful to understand the utility of the agent against pathogens that express resistance to older antimicrobial agents. The agent must be able to gain access to the site of infection at the dose and schedule chosen and at concentrations high enough to attain microbiologically effective targets [e.g. 1 or 2 log(10) (cfu/g) bacterial cell kill, accounting for between-patient variability]. Finally, therapeutic concentrations should be attained quickly at the primary site of infection to optimize clinical outcomes. When considering all of these factors, it is expected that ceftaroline fosamil will be a valuable addition to the therapeutic armamentarium for management of community-acquired pneumonia.
与确定治疗住院严重肺炎患者的抗菌药物的适当剂量和方案相关的因素是直接的。需要了解药物对可能遇到的肺炎典型病原体的效力。了解药物对表达对旧抗菌药物耐药的病原体的效用是有帮助的。该药物必须能够以所选剂量和方案进入感染部位，并达到足够高的浓度以达到微生物学有效的目标[例如，杀死 1 或 2 对数（10）（cfu/g）细菌细胞，考虑到患者间的变异性]。最后，治疗浓度应在感染的主要部位迅速达到，以优化临床结果。考虑到所有这些因素，预计头孢洛林酯将成为治疗社区获得性肺炎的治疗手段的宝贵补充。
